Peroxisome proliferator-activated receptor-γ and growth inhibition by its ligands in prostate cancer

Cancer Detection and Prevention

Volumn 32, Issue 3, 2008, Pages 259-266

  Nagata, Daisuke ^a   Yoshihiro, Hashimoto ^a   Nakanishi, Makoto ^a   Naruyama, Hiromichi ^a   Okada, Shinsuke ^a   Ando, Ryosuke ^a   Tozawa, Keiichi ^a   Kohri, Kenjiro ^a  

^a NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

Author keywords

Ligand; PPAR ; Prostate cancer; Prostate cancer cell line DU145; Prostate cancer cell line LNCaP; Prostate cancer cell line PC 3; Prostate cancer cell proliferation; Prostate specific antigen promoter; S phase cell arrest

Indexed keywords

15 DEOXY DELTA12,14 PROSTAGLANDIN J2; ANDROGEN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROSTATE SPECIFIC ANTIGEN; TROGLITAZONE;

ARTICLE; CANCER GROWTH; CELL CYCLE ARREST; CELL CYCLE S PHASE; CELL DIFFERENTIATION; CELL GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; DNA SYNTHESIS INHIBITION; DOSE RESPONSE; DOWN REGULATION; DRUG EFFECT; GENE ACTIVITY; GROWTH INHIBITION; HUMAN; HUMAN CELL; HUMAN TISSUE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; REPORTER GENE;

ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL PROLIFERATION; CHROMANS; FLOW CYTOMETRY; HUMANS; IMMUNOHISTOCHEMISTRY; LIGANDS; MALE; PPAR GAMMA; PROMOTER REGIONS, GENETIC; PROSTAGLANDIN D2; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; THIAZOLIDINEDIONES; TRANSFECTION;

EID: 52949088623     PISSN: 0361090X     EISSN: 15251500     Source Type: Journal    
DOI: 10.1016/j.cdp.2008.05.008     Document Type: Article

References (32)

1. Jemal A., Murray T., Samuels A., Ghafoor A., Ward E., and Thun M.J. Cancer statistics. CA Cancer J Clin 53 (2003) 5-26
2. Mangelsdorf D.J., Thummel C., Beato M., Herrlich P., Schütz G., Umesono K., et al. The nuclear receptor superfamily: the second decade. Cell 83 (1995) 835-839
3. Yu K., Bayona W., Kallen C.B., Harding H.P., Ravera C.P., McMahon G., et al. Differential activation of peroxisome proliferator-activated receptors by eicosanoids. J Biol Chem 270 (1995) 23975-23983
4. Qi C., Zhu Y., and Reddy J.K. Peroxisome proliferator-activated receptors, coactivators, and downstream targets. Cell Biochem Biophys 32 (2000) 187-204
5. Kliewer S.A., Xu H.E., Lambert M.H., and Willson T.M. Peroxisome proliferator-activated receptors: from genes to physiology. Recent Prog Horm Res 56 (2001) 239-263
6. Kim M.J., Deplewski D., Ciletti N., Michel S., Reichert U., and Rosenfield R.L. Limited cooperation between peroxisome proliferator-activated receptors and retinoid X receptor agonists in sebocyte growth and development. Mol Genet Metab 74 (2001) 362-369
7. Soret B., Lee H.J., Finley E., Lee S.C., and Vernon R.G. Regulation of differentiation of sheep subcutaneous and abdominal preadipocytes in culture. J Endocrinol 161 (1999) 517-524
8. Fontaine C., Dubois G., Duguay Y., Helledie T., Vu-Dac N., Gervois P., et al. The orphan nuclear receptor Rev-Erbβ is a peroxisome proliferator-activated receptor (PPAR)-γ target gene and promotes PPAR-γ-induced adipocyte differentiation. J Biol Chem 278 (2003) 37672-37680
9. Mueller E., Sarraf P., Tontonoz P., Evans R.M., Martin K.J., Zhang M., et al. Terminal differentiation of human breast cancer through PPAR-γ. Mol Cell 1 (1998) 465-470
10. Allred C.D., and Kilogore M.W. Selective activation of PPARgamma in breast, colon, and lung cancer cell lines. Mol Cell Endocrinol 235 (2005) 21-29
11. Nomura S., Nakajima A., Ishimine S., Matsuhashi N., Kadowaki T., and Kaminishi M. Differential expression of peroxisome proliferator-activated receptor in histologically different human gastric cancer tissues. J Exp Clin Cancer Res 25 (2006) 443-448
12. Cesario R.M., Stone J., Yen W.C., Bissonnette R.P., and Lamph W.W. Differentiation and growth inhibition mediated via the RXR:PPARgamma heterodimer in colon cancer. Cancer Lett 240 (2006) 225-233
13. Kristiansen G., Jacob J., Buckendahl A.C., Grutzmann R., Dietel M., and Pilarsky C. Peroxisome proliferator-activated receptor gamma is highly expressed in pancreatic cancer and is associated with shorter overall survival times. Clin Cancer Res 12 (2006) 6444-6451
14. Soares A.F., Nosjean O., Cozzone D., Lagarde M., and Geloen A. Covalent binding of 15-deoxy-delta12,14-prostaglandin J2 to PPAR gamma. Biochem Biophys Res Commun 337 (2005) 521-525
15. Murphy G.J., and Holder J.C. PPAR-gamma agonists: therapeutic role in diabetes, inflammation and cancer. Trends Pharmacol Sci 21 (2000) 469-474
16. Olefsky J.M., and Saltiel A.R. PPAR gamma and the treatment of insulin resistance. Trends Endocrinol Metab 11 (2000) 362-368
17. Willson T.M., Lambert M.H., and Kliewer S.A. Peroxisome proliferator-activated receptor gamma and metabolic disease. Annu Rev Biochem 70 (2001) 341-367
18. Motomura W., Takahashi N., Nagamine M., Sawamukai M., Tanno S., Kohgo Y., et al. Growth arrest by troglitazone is mediated by p27Kip1 accumulation, which results from dual inhibition of proteasome activity and Skp2 expression in human hepatocellular carcinoma cells. Int J Cancer 108 (2004) 41-46
19. Han S., Sidell N., Fisher P.B., and Roman J. Up-regulation of p21 gene expression by peroxisome proliferator-activated receptor gamma in human lung carcinoma cells. Clin Cancer Res 10 (2004) 1911-1919
20. Radhakrishnan S.K., and Gartel A. The PPAR-gamma agonist pioglitazone post-transcriptionally induces p21 in PC3 prostate cancer but not in other cell lines. Cell Cycle 4 (2005) 582-584
21. Fujii D., Yoshida K., Tanabe K., Hihara J., and Toge T. The ligands of peroxisome proliferator-activated receptor (PPAR) gamma inhibit growth of human esophageal carcinoma cells through induction of apoptosis and cell cycle arrest. Anticancer Res 24 (2004) 1409-1416
22. Nakanishi M., Robetorye R.S., Adami G.R., Pereira-Smith O.M., and Smith J.R. Identification of the active region of the DNA synthesis inhibitory gene p21 Sdi1/CIP1/WAF1. EMBO J 14 (1995) 555-563
23. Eligini S., Banfi C., Brambilla M., Camera M., Barbieri S.S., Poma F., et al. 15-deoxy-delta12,14-Prostaglandin J2 inhibits tissue factor expression in human macrophages and endothelial cells: evidence for ERK1/2 signaling pathway blockade. Thromb Haemost 7 (2002) 524-532
24. Kubota T., Koshizuka K., Williamson E.A., Asou H., Said J.W., Holden S., et al. Ligand for peroxisome proliferator-activated receptor gamma has potent antitumor effects against human prostate cancer both in vitro and in vivo. Cancer Res 58 (1998) 3344-3352
25. Elstner E., Müller C., Koshijuka K., Williamson E.A., Park D., Asou H., et al. Ligands for peroxisome proliferator-activated receptor and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice. Proc Natl Acad Sci USA 95 (1998) 8806-8811
26. Fulzele S.V., Chatterjee A., Shaik M.S., Jackson T., Ichite N., Singh M., et al. 15-Deoxy-Delta12,14-prostaglandin J2 enhances docetaxel anti-tumor activity against A549 and H460 non-small-cell lung cancer cell lines and xenograft tumors. Anticancer Drugs 11 (2007) 65-78
27. Theocharis S., Margeli A., Vielh P., and Kouraklis G. Peroxisome proliferator-activated receptor-gamma ligands as cell-cycle modulators. Cancer Treat Rev 30 (2004) 545-554
28. He B., Gampe R.T., Kole A.J., Hnat A.T., Stanley T.B., An G., et al. Structural basis for androgen receptor interdomain and coactivator interactions suggests a transition in nuclear receptor activation function dominance. Mol Cell 16 (2004) 425-438
29. Estebanez-Perpina E., Moore J.M., Mar E., Webb P., Fletterick R.J., and Guy R.K. The molecular mechanisms of coactivator utilization in ligand-dependent transactivation by the androgen receptor. J Biol Chem 280 (2005) 8060-8068
30. Edwards J., Krishna N.S., Mukherjee R., and Bartlett J.M. The role of c-Jun and c-Fos expression in androgen-independent prostate cancer. J Pathol 204 (2004) 153-158
31. Chen S.Y., Cai C., Fisher C.J., Zheng Z., Omwancha J., Hsieh C.L., et al. c-Jun enhancement of androgen receptor transactivation is associated with prostate cancer cell proliferation. Oncogene 25 (2006) 7212-7223
32. Shappell S.B., Gupta R.A., Manning S., Whitehead R., Boeglin W.E., Wheeler T.M., et al. 15S-Hydroxyeicosatetraenoic acid activates peroxisome proliferator-activated receptor gamma and inhibits proliferation in PC3 prostate carcinoma cells. Cancer Res 61 (2001) 497-503